Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.46 |
| ▸ | CFD | P00746 | 5/20 | 0.42 |
| ▸ | F11 | P03951 | 5/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.42 |
| ▸ | PLG | P00747 | 3/20 | 0.42 |
| ▸ | PLAU | P00749 | 3/20 | 0.42 |
| ▸ | F7 | P08709 | 3/20 | 0.42 |
| ▸ | TPSB2 | P20231 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | F9 | P00740 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145254 | 1.00 | L3MBTL1 (0.52) | L3MBTL1CXCL8CFDF11KLKB1 | |
| SCHEMBL3145731 | 0.84 | CXCL8 (0.39) | L3MBTL1CXCL8AKR1B1LTB4R | |
| SCHEMBL3145738 | 0.84 | CXCL8 (0.39) | L3MBTL1CXCL8AKR1B1LTB4R | |
| SCHEMBL3144823 | 0.83 | L3MBTL1 (0.50) | L3MBTL1CXCL8CFDF11KLKB1 | |
| SCHEMBL3140525 | 0.81 | CHRM1 (0.43) | CXCL8CHRM1 | |
| SCHEMBL3140532 | 0.81 | CHRM1 (0.43) | CXCL8CHRM1 | |
| SCHEMBL3150059 | 0.81 | MAPT (0.47) | CXCL8CHRM1 | |
| SCHEMBL3150056 | 0.81 | MAPT (0.47) | CXCL8CHRM1 | |
| SCHEMBL3143895 | 0.79 | PPARD (0.42) | PPARD | |
| SCHEMBL3143898 | 0.79 | PPARD (0.42) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | L3MBTL1 4254/4885CXCL8 942/4885CFD 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.